DESCRIPTION OF BUSINESS (Details Narrative) |
12 Months Ended | ||
|---|---|---|---|
Jul. 17, 2019 |
Jul. 15, 2019
shares
|
Dec. 31, 2020 |
|
| US [Member] | |||
| Description Of Business [Line Items] | |||
| Orphan drug designation provides market exclusivity period after marketing approval | 7 years | ||
| EU [Member] | |||
| Description Of Business [Line Items] | |||
| Orphan drug designation provides market exclusivity period after marketing approval | 10 years | ||
| Orphan drug designation provides additional marketing exclusivity period | 2 years | ||
| Telemynd [Member] | |||
| Description Of Business [Line Items] | |||
| Common stock shares, stock split ratio | 1 | ||
| Emmaus Life Sciences, Inc. [Member] | |||
| Description Of Business [Line Items] | |||
| Reverse split, conversion ratio | 0.167 | ||
| Reverse split | 1-for-6 |
| X | ||||||||||
- Definition Description of business. No definition available.
|
| X | ||||||||||
- Definition Orphan Drug designation provides additional marketing exclusivity period. No definition available.
|
| X | ||||||||||
- Definition Orphan Drug designation provides market exclusivity period after marketing approval. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued during the period as a result of a stock split. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|